secwatch.observer — SEC 8-K summary
======================================

Issuer:     HARROW, INC. (HROW)
CIK:        0001360214
Form:       8-K
Filed at:   2024-01-03T23:59:59+00:00
Accession:  0001493152-24-000192
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.02, 8.01, 5.02, 5.05, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harrow terminates $18.4M Melt loan, takes ~47% equity stake; appoints Saharek division president
--------------------------------------------------------------------------------

- Terminated Loan Agreement with Melt; received 2.26M Series B-1 and 74k Series B preferred shares in full settlement of ~$18.4M outstanding.
- After settlement, Harrow holds ~47% of Melt's equity (including 3.5M common shares) plus royalty rights on Melt drug candidates.
- John P. Saharek appointed President/CEO of ImprimisRx division effective Jan 2, 2024; base salary $450K, target bonus 50%.
- Melt received FDA support for MELT-300 Phase 3 program; expects to begin Phase 3 in Q1 2024, potentially benefiting Harrow's stake.
- Code of Business Conduct and Ethics amended to update corporate name and clarify political activities; no waivers granted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1360214/000149315224000192/0001493152-24-000192-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1360214/000149315224000192/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-000192

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer